This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_DIGESTIVE_ORGANS_NAS_EXALLC for full statistics.
Malignant neoplasm of other and ill-defined digestive organs
C3_DIGESTIVE_ORGANS_NAS
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
248 |
4. Check minimum number of eventsNone |
248 |
5. Include endpointsNone |
248 |
6. Filter based on genotype QC (FinnGen only) |
248 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and ill-defined digestive organs
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of digestive organs
- Malignant neoplasm of digestive organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 248 | 110 | 138 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 74.36 | 76.31 | 72.81 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 231
- Matched controls
- 2310
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8140/3-C26.9
ICD-O-3
Adenocarcinoma, NOS, of gastrointestinal tract, NOS
+∞
85.9
77
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
396.7
83.4
79
*
130
Kela drug reimbursment
Malignant tumour
15.4
58.6
107
122
Z51.5
ICD-10 Finland
Palliative care
14.4
43.8
79
80
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
461.3
40.4
39
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
23.4
38.6
56
31
8000/3-C26.9
ICD-O-3
Neoplasm, malignant of gastrointestinal tract, NOS
+∞
37.5
35
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
29.1
34.8
47
20
N02AA05
ATC
oxycodone; systemic
6.6
31.9
99
236
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
16.0
31.3
52
41
A04AA02
ATC
granisetron; systemic, transdermal
13.2
29.8
54
52
A03FA01
ATC
metoclopramide; systemic, rectal
5.4
27.8
105
308
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
46.0
26.6
32
8
H02AB02
ATC
dexamethasone; systemic
7.2
24.0
63
114
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
19.3
21.2
32
19
L01BC06
ATC
capecitabine; oral
12.0
19.5
36
35
JN4BD
NOMESCO Finland
Extensive body CT
5.1
17.8
62
155
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.1
17.1
31
29
C80.92
ICD-10 Finland
Malignant tumor without specified localization adenocarcinoma
+∞
16.9
16
*
C26.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of digestive system
182.4
16.7
17
*
8140/3-C26.0
ICD-O-3
Adenocarcinoma, NOS, of intestinal tract, NOS
+∞
15.8
15
*
JN4AD
NOMESCO Finland
Body CT examination
5.8
15.2
45
92
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
12.6
14.2
25
22
8000/3-C26.0
ICD-O-3
Neoplasm, malignant of intestinal tract, NOS
+∞
13.7
13
*
R18
ICD-10 Finland
Ascites
12.6
13.6
24
21
WF049
NOMESCO Finland
Radiotherapy of metastasis
10.7
13.6
26
27
JAH00
NOMESCO Finland
Laparotomy
9.6
12.9
26
30
8010/3-C26.9
ICD-O-3
Carcinoma, NOS, of gastrointestinal tract, NOS
+∞
12.6
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
5.9
12.3
35
68
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
17.6
11.9
18
11
8936/3-C26.9
ICD-O-3
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
+∞
11.5
11
*
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
17.7
10.0
15
9
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
21.1
9.9
14
7
A04AA01
ATC
ondansetron; systemic, rectal
4.8
9.7
32
74
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
104.0
9.5
10
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
9.3
92
477
A06AH03
ATC
naloxegol; oral
28.7
8.6
11
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
21.0
8.6
12
6
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
93.2
8.5
9
*
WZC30
NOMESCO Finland
Teaching
3.2
8.1
44
157
WX302
NOMESCO Finland
Thoracal epidural anesthesy
5.0
7.8
24
52
H01CB03
ATC
lanreotide; parenteral
46.5
7.8
9
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
46.5
7.8
9
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.3
7.4
83
452
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
7.3
7
*
D77
ICPC
Malignant digestive neopl other/NOS
31.0
7.2
9
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
31.0
7.2
9
*
B01AB10
ATC
tinzaparin; parenteral
3.7
7.0
30
90
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.0
7.0
40
149
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.9
6.8
43
171
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.9
6.5
26
73
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
6.5
63
316
189
Kela drug reimbursment
Imatinib
71.7
6.5
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
9.7
6.4
12
13
8240/3-C26.9
ICD-O-3
Neuroendocrine tumor, NOS, of gastrointestinal tract, NOS
+∞
6.3
6
*
8480/3-C26.9
ICD-O-3
Mucinous adenocarcinoma of gastrointestinal tract, NOS
+∞
6.3
6
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.8
6.2
42
172
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
135
227
11.85
87.73
3.7
4.3
203.1
72.4
ug/l
0.95
121
193
75
88
11.78
62.36
3.5
3.4
6133.3
1472.1
u/ml
0.98
65
75
33
29
12.97
32.46
1.8
1.5
19.8
16.0
ug/l
0.51
33
29
28
22
14.21
29.35
4.5
3.5
9.3
4.1
nmol/l
0.43
28
22
42
72
6.82
24.42
2.0
2.3
189.0
52.3
u/ml
2.31
42
66
169
1008
3.12
15.85
13.0
6.1
16.2
11.7
umol/l
1.40
164
948
117
577
2.94
15.49
2.9
2.4
42.5
56.5
u/l
6.68
108
537
15
7
22.67
10.81
6.1
5.7
186.5
116.1
nmol/l
—
15
7
141
869
2.44
10.71
7.8
4.4
30.7
34.6
g/l
8.78
135
804
156
1019
2.43
10.22
15.0
8.7
5.3
4.3
e9/l
3.10
141
884
13
20
6.80
8.14
1.2
1.3
47858.6
63000.4
e6/l
—
7
13
48
214
2.54
7.06
3.4
2.8
19.9
9.8
umol/l
1.00
48
186
77
425
2.18
6.94
2.5
2.3
—
—
—
0
0
122
811
1.99
6.57
4.6
4.3
—
—
—
0
0
131
1699
0.51
6.13
3.5
5.2
2.6
2.6
mmol/l
0.19
111
1526
10
16
6.47
6.00
5.9
3.1
68.5
108.4
u/ml
—
10
16
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
71
3.30
5.77
3.3
2.2
0.4
0.3
u/ml
0.76
16
41
127
1648
0.53
5.67
3.2
4.6
4.5
4.5
mmol/l
0.19
110
1494
127
1638
0.54
5.38
3.1
4.6
1.4
1.4
mmol/l
0.67
112
1467
179
1420
1.93
5.11
15.3
7.5
132.5
80.6
u/l
7.20
170
1313
124
1587
0.56
4.74
2.9
4.1
1.4
1.3
mmol/l
0.68
106
1413
54
874
0.51
4.58
2.4
2.5
—
—
—
0
0
136
1691
0.57
4.57
3.3
4.9
6.2
6.1
mmol/l
0.35
112
1506
130
960
1.74
4.44
6.1
6.5
1.2
1.2
mmol/l
0.42
105
792
128
1611
0.57
4.40
5.4
6.4
43.1
41.4
mmol/mol
0.97
110
1478
121
887
1.71
4.16
6.0
5.6
1.2
1.2
mmol/l
0.85
116
785
52
321
1.78
3.18
11.6
29.4
1.8
1.3
inr
—
7
32
51
316
1.77
3.08
2.4
1.8
29.5
29.6
s
0.06
51
302
13
48
2.80
2.76
1.3
1.5
—
—
—
0
0
140
1142
1.52
2.65
4.6
4.5
7.1
6.8
mmol/l
0.84
132
1083
12
47
2.63
2.30
1.3
1.2
—
—
—
0
0
43
281
1.64
2.14
4.6
5.6
101.2
103.9
mmol/l
1.80
43
270
28
449
0.58
2.04
3.7
3.1
0.8
0.9
ug/l
0.04
18
309
11
44
2.57
2.04
1.5
1.5
—
—
—
0
0
11
44
2.57
2.04
1.5
1.5
—
—
—
0
0
40
586
0.62
2.03
3.7
3.8
28.2
10.2
mg/mmol
0.35
22
387
7
22
3.24
1.89
1.3
1.4
435.1
342.6
u/l
—
7
22
137
1558
0.73
1.65
3.4
4.6
1.9
2.0
mu/l
0.33
121
1361
23
138
1.73
1.58
1.4
1.4
—
—
—
0
0
145
1628
0.74
1.55
27.7
16.3
76.5
72.2
ml/min/173m2
1.23
130
1330
31
203
1.60
1.55
3.2
4.1
3.0
1.6
mmol/l
0.65
25
163
9
40
2.30
1.41
1.6
1.4
—
—
—
0
0
0
38
0.00
1.35
0.0
1.2
—
1.7
—
0
8
24
154
1.62
1.31
1.5
1.7
—
—
—
0
0
21
321
0.62
1.27
1.2
1.2
0.7
0.9
u/ml
—
8
85
36
256
1.47
1.27
3.7
5.8
11.5
11.5
kpa
0.01
36
244
36
256
1.47
1.27
3.7
5.9
5.0
5.0
kpa
0.01
36
243
0
34
0.00
1.17
0.0
1.2
—
—
—
0
0
0
34
0.00
1.17
0.0
1.1
—
233.4
—
0
15
49
625
0.73
1.16
3.7
4.6
23.9
21.9
%
0.29
23
323
0
36
0.00
1.15
0.0
1.1
—
—
—
0
0
35
255
1.43
1.10
3.6
5.9
1.5
1.3
mmol/l
0.10
29
197
38
497
0.72
1.05
1.2
1.7
21.0
20.5
nmol/l
0.06
32
416
5
22
2.30
1.04
1.2
1.3
—
—
—
0
0
46
356
1.36
1.03
1.8
1.9
—
—
—
0
0
67
804
0.77
1.03
1.6
2.1
83.4
92.3
pmol/l
0.84
34
410
15
230
0.63
0.94
2.6
4.6
28.0
31.5
%
—
6
148
11
182
0.59
0.94
1.1
1.4
—
—
—
0
0
59
710
0.78
0.91
1.9
2.4
71.2
78.0
nmol/l
0.83
50
610
67
793
0.79
0.90
3.9
5.1
2.5
2.8
ug/l
0.20
58
696
98
854
1.24
0.90
3.4
4.5
32.8
48.2
ng/l
1.10
77
653
12
73
1.68
0.83
1.0
1.2
—
—
—
0
0
113
1254
0.82
0.83
3.0
3.7
15.4
15.0
pmol/l
0.96
96
1085
22
156
1.45
0.82
3.7
6.6
25.9
24.6
mmol/l
0.78
22
144
117
1050
1.22
0.79
3.4
3.1
124.0
54.0
u/l
2.75
110
967
33
255
1.34
0.77
1.7
1.8
—
—
—
0
0
0
28
0.00
0.76
0.0
1.6
—
—
—
0
0
79
903
0.82
0.76
3.6
4.4
0.0
0.0
estimate
0.00
22
167
80
911
0.82
0.74
3.6
4.5
0.0
0.0
estimate
0.00
22
159
80
902
0.83
0.65
4.8
6.0
0.0
0.0
estimate
0.00
23
164
0
20
0.00
0.60
0.0
1.5
—
3.1
—
0
7
11
72
1.55
0.60
2.4
3.4
—
—
—
0
0
28
222
1.29
0.57
4.3
4.0
—
—
—
0
0
6
38
1.59
0.54
1.2
1.7
—
—
—
0
0
63
710
0.85
0.50
2.3
2.9
441.5
147.3
ug/l
0.61
56
644
12
84
1.45
0.50
1.8
2.2
—
—
—
0
0
11
76
1.47
0.49
1.5
1.9
—
—
—
0
0
60
530
1.17
0.46
2.0
2.2
3.1
3.3
mg/l
0.44
51
460
130
1381
0.88
0.45
31.5
21.2
14.9
14.0
%
5.45
130
1347
39
335
1.19
0.41
1.6
2.6
13.1
12.4
umol/l
0.18
33
305
182
1886
0.87
0.41
35.1
25.1
4.1
4.4
e12/l
10.60
174
1819
30
251
1.22
0.41
1.7
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
4.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
182
1751
1.15
0.40
26.6
17.5
44.5
25.7
mg/l
5.98
173
1443
40
458
0.85
0.39
1.7
1.8
362500501.5
436.1
pmol/l
0.49
32
381
25
208
1.22
0.37
1.7
2.8
3.2
7.2
ug/l
1.72
17
183
6
41
1.47
0.36
1.0
1.8
—
—
—
0
0
14
108
1.31
0.36
1.4
3.9
2.2
1.4
mmol/l
0.91
14
103
176
1821
0.88
0.35
31.6
20.4
81.5
85.0
umol/l
0.75
176
1821
10
133
0.74
0.34
2.2
1.7
—
—
—
0
0
31
350
0.87
0.26
3.1
3.0
2.9
1.4
e6/l
0.36
12
203
62
573
1.11
0.26
3.6
3.5
1.2
0.4
e6/l
1.73
46
440
67
717
0.91
0.24
3.8
4.8
—
—
—
0
0
13
106
1.24
0.23
5.2
7.2
24.2
24.8
mmol/l
0.40
13
96
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
3.5
—
0
8
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
33
298
1.12
0.20
1.8
2.5
28.6
21.6
%
0.65
23
256
11
91
1.22
0.18
1.5
3.6
3.5
4.0
mmol/l
2.31
11
80
68
717
0.93
0.17
2.9
3.4
1773.6
1863.0
ng/l
0.07
59
601
13
148
0.87
0.13
1.2
1.7
1.5
1.6
%
—
8
120
77
740
1.06
0.13
3.3
3.6
—
—
—
0
0
6
54
1.11
0.09
1.0
1.7
—
—
—
0
0
6
54
1.11
0.09
1.0
1.7
—
—
—
0
0
8
78
1.03
0.07
1.0
2.3
—
—
—
0
0
181
1828
0.96
0.07
28.8
20.5
4.0
4.0
mmol/l
0.06
175
1770
180
1818
0.96
0.07
17.8
10.8
33.2
24.4
u/l
2.71
172
1734
47
455
1.04
0.05
1.8
1.8
1169.5
1211.7
nmol/l
0.08
39
340
50
486
1.04
0.05
3.4
2.8
7414.9
9293.0
umol/l
0.09
41
405
130
1315
0.98
0.04
3.2
4.1
24.5
14.3
mm/h
4.21
118
1190
149
1475
1.02
0.04
25.1
18.1
36.4
39.0
%
2.63
97
937
32
331
0.96
0.04
3.1
3.3
4.2
2.9
e6/l
0.33
13
185
181
1822
0.97
0.04
28.5
20.5
138.0
139.6
mmol/l
9.48
175
1762
25
242
1.04
0.02
10.8
9.3
—
—
—
0
0
14
145
0.96
0.00
1.2
1.3
—
—
—
0
0
51
513
0.99
0.00
4.1
4.7
0.0
0.0
estimate
0.00
19
158
16
159
1.01
0.00
5.8
3.3
57.6
55.6
ml/min/173m2
—
5
72
5
58
0.86
0.00
1.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.0
2.6
0.0
0.5
g/l
—
6
61
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
3.7
—
119.2
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
6
65
0.92
0.00
1.0
2.6
31.5
37.2
g/l
—
6
57
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
44.8
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_DIGESTIVE_ORGANS_NAS – Malignant neoplasm of other and ill-defined digestive organs
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).